Quantcast

Evolus to Release Fourth Quarter and Full Year 2018 Financial Results and Provide a Business Update on Monday, March 18, 2019

By GlobeNewswire,  March 15, 2019, 04:01:00 PM EDT


IRVINE, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will release fourth quarter and full year 2018 financial results and provide a business update after the close of U.S. financial markets on Monday, March 18, 2019.

Management will host a conference call and live webcast to discuss Evolus' financial results at 4:30 p.m. ET that same day. A question and answer session will follow management remarks.

The dial-in numbers for the conference call are (866) 916-2317 for domestic callers and (703) 925-2662 for international callers.  The conference ID is 8045909.



A replay of the call will be available following its completion through March 25, 2019. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID 8045909.

A live audio webcast of the call will be available on the Investor Relations page of the Evolus, Inc. website, https://investors.evolus.com. A replay of the webcast will be archived on Evolus' website for 30 days following the completion of the call.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S Food and Drug Administration approved Jeuveau™ (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau™ is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: www.evolus.com.

Jeuveau™ is a trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investor Contacts:

Ashwin Agarwal, Evolus, Inc.

Vice President, Finance, Investor Relations & Treasury

Tel: +1-949-284-4559

Email: IR@Evolus.com

Brian Johnston, The Ruth Group

Tel: +1-646-536-7028

Email: IR@Evolus.com

Media Contacts:

Crystal Muilenburg, Evolus, Inc.

Vice President, Corporate Communications & Public Relations

Tel: +1-949-284-4506

Email: media@evolus.com

Source: Evolus

This article appears in: News Headlines

Referenced Stocks: EOLS










Today's Market Activity

NASDAQ 7637.54
-5.13  ▼  0.07%
DJIA 25516.83
14.51  ▲  0.06%
S&P 500 2798.36
-2.35  ▼  0.08%
Data as of Mar 25, 2019